To comprehensively evaluate the antitumor effect of defactinib in ESCC/CAFs coinjection xenografted model, the expression of Ki-67, CD31, and LYVE-1 in tumor tissues was measured with quantitative ELISA assays. Here, LYVE1 is linked to esophageal squamous cell carcinoma.